A phase I dose-finding study of silybin phosphatidylcholine (milk thistle) in patients with advanced hepatocellular carcinoma

Integrative Cancer Therapies

Volumn 13, Issue 1, 2014, Pages 46-53

  Siegel, Abby B ^a   Narayan, Rupa ^b   Rodriguez, Rosa ^a   Goyal, Abhishek ^a   Jacobson, Judith S ^a   Kelly, Kara ^a   Ladas, Elena ^a   Lunghofer, Paul J ^c   Hansen, Ryan J ^c   Gustafson, Daniel L ^c   Flaig, Thomas W ^d   Yann Tsai, Wei ^a   Wu, David P H ^a   Lee, Valerie ^a   Greenlee, Heather ^a  

^a Department of Medicine   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c Department of Environmental and Radiological Health Sciences   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

dietary supplement; hepatocellular carcinoma; herbal supplement; milk thistle; phase I clinical trial

Indexed keywords

ALPHA FETOPROTEIN; SILIBININ; SILIBININ GLUCURONIDE; SILYBIN PHOSPHATIDYLCHOLINE; SILYBUM MARIANUM EXTRACT; UNCLASSIFIED DRUG;

ADULT; ANEMIA; ARTICLE; ASCITES; ASTHENIA; CARDIOPULMONARY ARREST; CASE REPORT; CONSTIPATION; DEPRESSION; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG ERUPTION; DYSPNEA; FEMALE; HEMOPTYSIS; HUMAN; HYPERKALEMIA; HYPERTRANSAMINASEMIA; HYPONATREMIA; INFLAMMATION; LEG EDEMA; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LOW BACK PAIN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RECTUM HEMORRHAGE; SILYBUM MARIANUM; THROMBOCYTOPENIA; URINARY TRACT INFECTION; VOMITING;

DIETARY SUPPLEMENT; HEPATOCELLULAR CARCINOMA; HERBAL SUPPLEMENT; MILK THISTLE; PHASE I CLINICAL TRIAL;

ANTIOXIDANTS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIVER NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MILK THISTLE; PHOSPHATIDYLCHOLINES; SILYMARIN;

EID: 84892567968     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735413490798     Document Type: Article

References (20)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012 ; 62: 10-29
2. Olsen SK, Brown RS, Siegel AB. Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies. Therap Adv Gastroenterol. 2010 ; 3: 55-66
3. Llovet JM, Ricci S, Mazzaferro V, et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 ; 359: 378-390
4. Siegel AB, Olsen SK, Magun A, Brown RS. Sorafenib: where do we go from here?. Hepatology. 2010 ; 52: 360-369
5. Ladas EJ, Kroll DJ, Oberlies NH, et al. A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL). Cancer. 2010 ; 116: 506-513
6. Wagoner J, Morishima C, Graf TN, et al. Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation. PloS One. 2011 ; 6 (1). e16464
7. Kroll DJ, Shaw HS, Oberlies NH. Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies. Integr Cancer Ther. 2007 ; 6: 110-119
8. Hogan FS, Krishnegowda NK, Mikhailova M, Kahlenberg MS. Flavonoid, silibinin, inhibits proliferation and promotes cell-cycle arrest of human colon cancer. J Surg Res. 2007 ; 143: 58-65
9. Fried MW, Navarro VJ, Afdhal N, et al. Silymarin in NASH and C Hepatitis (SyNCH) Study Group. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial. JAMA. 2012 ; 308: 274-282
10. Hawke RL, Schrieber SJ, Soule TA, et al. SyNCH Trial Group. Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J Clin Pharmacol. 2010 ; 50: 434-449
11. Bethesda, MD: National Cancer Institute ; 2009:
12. Flaig TW, Gustafson DL, Su L-J, et al. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs. 2007 ; 25: 139-146
13. Flaig TW, Glode M, Gustafson D, et al. A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate. 2010 ; 70: 848-855
14. Vidlar A, Vostalova J, Ulrichova J, et al. The safety and efficacy of a silymarin and selenium combination in men after radical prostatectomy - a six month placebo-controlled double-blind clinical trial. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010 ; 154: 239-244
15. Sherman M, Bruix J, Porayko M, Tran T. AASLD Practice Guidelines Committee. Screening for hepatocellular carcinoma: the rationale for the American Association for the Study of Liver Diseases recommendations. Hepatology. 2012 ; 56: 793-796
16. Hollebecque A, Cattan S, Romano O, et al. Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score. Aliment Pharmacol Ther. 2011 ; 34: 1193-1201
17. Heffernan N, Cella D, Webster K, et al. Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy-hepatobiliary questionnaire. J Clin Oncol. 2002 ; 20: 2229-2239
18. Guo Y, Lu P, Farrell E, et al. In silico and in vitro pharmacogenetic analysis in mice. Proc Natl Acad Sci U S A. 2007 ; 104: 17735-17740
19. Llovet JM, Di Bisceglie AM, Bruix J, et al. Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008 ; 100: 698-711
20. Lencioni R, Kudo M, Ye SL, et al. First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study. Int J Clin Pract. 2012 ; 66: 675-683